RxDoctor Payments Data

Ryan Shipe, MD

Pulmonary Disease · Hopedale, MANPI 1194943316

Payments from drug & device makers

$146in general payments, 2019–2025

Across 8 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$53
  • Sanofi$24
  • AstraZeneca$20
  • Philips North America LLC$17
  • Regeneron Healthcare Solutions, Inc.$17
  • Amgen$15

What the payments were for

  • Food & beverage$146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$146 in reported general payments places this provider in the 35th percentile of 482 pulmonary disease providers in Massachusetts.

See all pulmonary disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$170,946
Medicare patients
707
Services billed
1,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter652$550,891
OfevNintedanib Esylate14$205,862
Breztri AerosphereBudesonide/Glycopyr/Formoterol193$133,657
Prolastin CAlpha-1-Proteinase Inhibitor13$111,316
Dupixent PenDupilumab29$105,328
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr161$94,132
Fasenra PenBenralizumab14$79,016
Breo ElliptaFluticasone/Vilanterol98$55,871
Spiriva RespimatTiotropium Bromide63$34,669
Incruse ElliptaUmeclidinium Bromide80$34,422
EliquisApixaban39$34,358
Advair HfaFluticasone Propion/Salmeterol77$27,781
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$17,849
Albuterol Sulfate HfaAlbuterol Sulfate473$16,719
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate52$15,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$53$745,7321,023 claims
AstraZenecaBreztri Aerosphere, Symbicort$20$147,723235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 482 pulmonary disease providers in Massachusetts.

Other pulmonary disease in Hopedale

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →